General Safety Profile Based on the preclinical dataset and the limited human exposure data: No prominent signal of hepatic, renal, or hematological toxicity at tested doses No prominent cardiovascular safety flag Pregnancy and lactation as with most research compounds, safety not established Long-term effects not characterized What Clinicians Should Actually Tell Patients For patients asking about 5-amino-1MQ, a reasonable response framework: What the compound is: A research-stage small molecule inhibiting NNMT with promising preclinical fat loss data
Thompson AB, Bohling T, Heires A, Linder J, Rennard SI
The oral administration of liposomal GSH reduced (60)Co levels in nearly all tissues by 12-43% compared to that observed for non-formulated GSH
Longevity-focused patients typically run a corrective loading phase (weekly NAD+ for 24 weeks) then move to monthly maintenance, often layered with glutathione IV for antioxidant defence and personalised vitamin therapy based on lab markers
Carnitine deficiency and hyperammonemia associated with valproic acid therapy
